Melanotan II Guide: Mechanism of Action, Dosage, and Research Status
Dr. Sieglinde Klaus
Scientific Editorial Team — Bergdorf Bioscience
Dr. Sieglinde Klaus
Scientific Editorial Team — Bergdorf Bioscience
Melanotan II (MT-2) is a synthetic cyclic heptapeptide and structural analog of the endogenous alpha-melanocyte-stimulating hormone (α-MSH). Developed in the 1980s at the University of Arizona, this peptide with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ acts as a non-selective agonist at the melanocortin receptors MC1R, MC3R, MC4R, and MC5R. In peptide chemistry research, Melanotan II serves as a valuable tool for investigating structure-activity relationships within the melanocortin peptide class.
Melanotan II, often abbreviated as MT-2 or MT-II, belongs to the family of melanocortin peptides. It is a cyclic lactam analog of α-MSH with a molecular weight of 1,024.2 Da and the molecular formula C₅₀H₆₉N₁₅O₉ (CAS number: 121062-08-6). The cyclic structure is formed by a lactam bridge between the ε-amino group of lysine and the γ-carboxy group of aspartic acid. This cyclization imparts significantly increased metabolic stability compared to linear α-MSH, as the compact ring structure hinders enzymatic degradation by peptidases. In competitive binding assays, MT-2 demonstrates high affinity for the receptors MC1R, MC3R, MC4R, and MC5R with Ki values in the sub-nanomolar to low-nanomolar range, while minimal affinity was measured for MC2R Dorr et al., 199600160-3). The lyophilized powder appears as a white to off-white preparation and is stable for long-term storage when handled correctly.
The mechanism of action of Melanotan II is based on its binding to melanocortin receptors, a group of five G-protein-coupled receptors (MC1R to MC5R). Upon activation of these receptors, intracellular cAMP accumulates, triggering downstream signaling cascades. Functional cAMP accumulation assays confirmed full agonist activity at MC1R, MC3R, MC4R, and MC5R with EC₅₀ values that correlated closely with binding affinities Dorr et al., 199600160-3). The MC1 receptor is predominantly expressed in skin melanocytes and plays a central role in melanogenesis; its activation leads to increased production of eumelanin. The receptors MC3R and MC4R are found primarily in the hypothalamus and are subjects of intense research in the fields of energy homeostasis and neuroendocrine signaling pathways. MC4R activation is also associated with pro-erectile effects via oxytocin signaling pathways Wessells et al., 200000875-1). MC5R is expressed in exocrine glands, among other locations, and its physiological function is not yet fully characterized.
In the clinical Phase I study by Dorr and colleagues, subcutaneous injections of MT-2 were administered five days a week for two consecutive weeks. The starting dose was 0.01 mg/kg of body weight, with increments of 0.005 mg/kg up to a maximum of 0.03 mg/kg. At a dose of 0.03 mg/kg, Grade II somnolence was observed in one of two subjects, leading to the recommended single dose for further Phase I studies being set at 0.025 mg/kg/day Dorr et al., 199600160-3). In preclinical studies on rats, the dosages used vary considerably depending on the research question; typical intracerebroventricular doses range from 0.5 to 1.0 nmol for investigating central melanocortin effects. For in vitro studies, concentrations in the nanomolar range (1 to 100 nM) are used for receptor characterization. Each vial from Bergdorf Bioscience contains 10 mg of lyophilized MT-2, allowing for flexible dosing in various experimental protocols. Order Melanotan II now
The cyclic structure and the resulting resistance to peptidase degradation provide Melanotan II with a significantly extended plasma half-life compared to linear α-MSH analogs. Following intravenous administration, the plasma half-life is approximately 33 to 40 minutes, representing a substantial improvement over the rapid degradation of linear melanocortin peptides Ugwu et al., 1994. Product metadata from Bergdorf Bioscience indicates a biological half-life of approximately 33 to 36 hours, which refers to the functional duration of effect and should not be equated with the elimination half-life. Bioavailability after subcutaneous application is relatively favorable for cyclic peptides, as the compact ring structure facilitates absorption through the subcutaneous tissue. In the study by Dorr et al., measurable plasma levels with reproducible kinetics were observed after subcutaneous administration of 0.025 mg/kg Dorr et al., 199600160-3). The extended duration of action allows for daily or every-other-day administration in research protocols.
The research literature on Melanotan II covers several well-documented areas of effect. In the field of melanogenesis, studies showed a dose-dependent increase in eumelanin production via the MC1R signaling pathway, qualifying MT-2 as a tool for exploring pigmentation-relevant mechanisms. Regarding energy homeostasis, studies in rats demonstrated that chronic activation of the central melanocortin system by MT-2 led to a significant reduction in body mass without the need for caloric restriction Lee et al., 2017. Choi and colleagues demonstrated that MT-2 affects both subcutaneous and visceral adipose tissue in rodent models Choi et al., 2007. In the neurological field, it was shown that the potent melanocortin receptor agonist MT-2 promotes peripheral nerve regeneration and exhibits neuroprotective properties in rat models Catania et al., 200300870-0). Furthermore, MT-2 reduced the orexigenic and adipogenic effects of Neuropeptide Y (NPY) in male rats Raposinho et al., 2003.
Proper storage of Melanotan II is crucial for maintaining peptide integrity. In its lyophilized state, MT-2 should be stored at 2 to 8 °C in the refrigerator; for long-term storage, a temperature of minus 20 °C is recommended. The peptide must be protected from light and kept in a dry environment, as moisture can compromise the stability of the lyophilized powder. Bacteriostatic water is used for reconstitution. The addition should be slow and along the glass wall of the vial to minimize foam formation, which can lead to denaturation of the peptide. After reconstitution, the solution should be stored at 2 to 8 °C and used within an appropriate timeframe. Repeated freezing and thawing should be avoided, as this can damage the peptide structure through ice recrystallization. Lyophilization at Bergdorf Bioscience ensures high long-term stability; every batch is tested via HPLC for a purity of at least 99% and is delivered with a Certificate of Analysis (CoA).
For reproducible research results, the purity of the peptide used is a critical factor. In academic research, an HPLC purity of at least 95% is typically required; for studies involving sensitive receptor binding assays or in vivo models, purities of 98% and higher are preferred. Impurities can cause false-positive results in binding studies or induce cytotoxic effects in cell-based assays that are incorrectly attributed to the peptide under investigation. The Melanotan II available from Bergdorf Bioscience features a purity of at least 99%, determined by high-performance liquid chromatography (HPLC). Additionally, each batch undergoes mass spectrometric identity confirmation to verify the correct molecular mass of 1,024.2 Da. Full batch documentation, including the HPLC chromatogram and mass spectrum, is traceable via the Certificate of Analysis (CoA). This rigorous quality control is particularly relevant when investigating selectivity toward individual melanocortin receptor subtypes, where even minor impurities can distort results.
Melanotan I (Afamelanotide) and Melanotan II are both synthetic analogs of α-MSH but differ fundamentally in structure and receptor selectivity. Melanotan I is a linear tridecapeptide with 13 amino acids and acts as a selective MC1R agonist. Melanotan II, on the other hand, is a cyclic heptapeptide with only seven amino acids and binds non-selectively to MC1R, MC3R, MC4R, and MC5R. This broader receptor affinity explains the more diverse research applications of MT-2 compared to MT-I. Pharmacokinetically, the two peptides also differ significantly: the plasma half-life of Melanotan I after subcutaneous administration is 0.8 to 1.7 hours in the beta phase Levine et al., 199700547-8), while MT-2 has a shorter elimination half-life of 33 to 40 minutes but a significantly longer functional duration of action of 33 to 36 hours. Melanotan I was approved as a drug under the name Afamelanotide for the treatment of erythropoietic protoporphyria, while Melanotan II has not yet been approved for any therapeutic indication and is available exclusively as a research peptide.
In the clinical Phase I study, the most common reported side effects at a dose of 0.025 mg/kg were: nausea (classified as severe in 12.9% of subjects), yawning, facial flushing, and transient fatigue Dorr et al., 199600160-3). At a dose of 0.03 mg/kg, Grade II somnolence occurred in one subject. Since MT-2 can cross the blood-brain barrier and acts as a non-selective agonist at multiple MC receptors, central effects such as appetite reduction and mood changes are described in the research literature. One case report documented systemic toxicity with rhabdomyolysis and renal dysfunction after uncontrolled use Habbema et al., 2012. Long-term safety concerns primarily relate to potential changes in melanocytic nevi; several case reports describe the appearance of new or altered moles in temporal connection with use. These observations underscore the need for further systematic studies on long-term safety.
Current research on Melanotan II spans several disciplines. In the field of neuroscience, a study by Minakova and colleagues showed that MT-2 reversed autistic features in a mouse model with maternal immune activation, highlighting the role of the melanocortin system in neuronal development Minakova et al., 2019. In obesity research, chronic activation of the central melanocortin system is being investigated as an approach to reduce body mass without caloric restriction Lee et al., 2017. In the field of regenerative medicine, the neuroprotective properties of melanocortin agonists remain an active area of research. Qualitative studies on user experiences in online forums provide additional insights into application patterns and perceived effects Brennan et al., 2021. The non-selective receptor binding of MT-2 makes it a versatile research tool, though this lack of selectivity also presents limitations that must be considered when interpreting study results.
Bacteriostatic water is recommended for reconstitution. Add the solvent slowly along the wall of the vial and swirl the vial gently without shaking. The solution should be clear and colorless; cloudy solutions indicate contamination or degradation and should not be used.
Reconstituted MT-2 should be stored at 2 to 8 °C and used within 28 days. Repeated freezing and thawing compromises the stability of the peptide and should be avoided.
The most common method is high-performance liquid chromatography (HPLC), supplemented by mass spectrometry (LC-MS) for identity confirmation. In a comparative study, HPLC and bioassay proved to be complementary methods for determining plasma levels of MT-2 Ugwu et al., 1994.
In research, MT-2 is occasionally studied in combination with other peptides, such as Neuropeptide Y (NPY), to investigate opposing effects on energy homeostasis. Potential interactions should be carefully considered in experimental protocols, as the non-selective receptor binding of MT-2 influences multiple signaling pathways.
No. Melanotan II has not yet been approved for any therapeutic indication and is available exclusively as a research peptide. All products offered by Bergdorf Bioscience are intended solely for research purposes.